IPT in people living with HIV in Myanmar: a five-fold decrease in incidence of TB disease and all-cause mortality

This study aims to assess the effect of isoniazid (INH) preventive therapy (IPT) on the risk of TB disease and mortality

Abstract

This article is set in Myanmar, a country with a high human immunodeficiency virus-tuberculosis (HIV-TB) burden, where the tuberculin skin test or interferon-gamma release assays are not routinely available for the diagnosis of latent tuberculous infection. The study aims to assess the effect of isoniazid (INH) preventive therapy (IPT) on the risk of TB disease and mortality among people living with HIV (PLHIV).

This research was supported by the UK Department for International Development’s Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)

Citation

Kyaw NTT, Kumar AMV, Kyaw KWY, Satyanarayana S, Magee MJ, Min AC, Moe J, Aung ZZ, Aung TK, Oo MM, Soe KT, Oo HN, Aung ST, Harries AD. IPT in people living with HIV in Myanmar: a five-fold decrease in incidence of TB disease and all-cause mortality. The International Journal of Tuberculosis and Lung Disease. 2019;23(3):322–30.

IPT in people living with HIV in Myanmar: a five-fold decrease in incidence of TB disease and all-cause mortality

Updates to this page

Published 1 March 2019